Mutation of the DR5/TRAIL receptor 2 gene is infrequent in hepatocellular carcinoma

被引：24

作者：

Jeng, YM ^{[1
]}

Hsu, HC ^{[1
]}

机构：

[1] Natl Taiwan Univ Hosp, Dept Pathol, Taipei 100, Taiwan

来源：

CANCER LETTERS | 2002年 / 181卷 / 02期

关键词：

hepatocellular carcinoma; mutation; tumor necrosis factor-related apoptosis-inducing ligand-receptor 2;

D O I：

10.1016/S0304-3835(02)00051-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chromosome 8p21-22 is a frequent site of loss of heterozygosity in many types of cancer, including hepatocellular carcinoma (HCC). Tumor necrosis factor-related apoptosis-inducing ligand-receptor 2 (TRAIL-R2/DR5), a member of tumor necrosis factor receptor family, is mapped to chromosome 8p21-22. Mutations of TRAIL-R2 have been detected in lung cancer, breast cancer, head and neck cancer, and non-Hodgkin's lymphoma. In this study, we analyzed the entire coding regions and all splicing sites of TRAIL-R2 in 40 HCCs and the death domain region in additional 60 HCCs. We could detect one point mutation in the death domain in only one HCC (1%). Our data suggest that somatic mutations of TRAIL-R2 gene do not play an important role in the carcinogenesis of HCC. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：205 / 208

页数：4

共 19 条

[1] Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas [J].